Salovum

DIETARY_SUPPLEMENT8 trials

Sponsors

St. Erik Eye Hospital, Peter Siesjö, Henrik Lindman

Conditions

Adverse Drug EventBrain TraumaCerebral EdemaChemotherapy EffectDiarrheaEarly-stage Breast CancerEdema BrainGlaucoma

Phase 1

Antisecretory Factor in Primary Glioblastoma 1

CompletedNCT04116138

Peter SiesjöCerebral Edema, Chemotherapy Effect, Glioblastoma

Start: 2019-09-01End: 2021-03-31Updated: 2021-04-28

Phase 2

Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury

WithdrawnNCT03453749

Peter SiesjöEdema Brain, Head Trauma, Intensive Care Neurological Disorder

Start: 2018-03-01End: 2018-12-10Updated: 2018-12-12

Antisecretory Factor In Severe Traumatic Brain Injury

RecruitingNCT04117672

Peter SiesjöTraumatic Brain Injury

Start: 2020-03-10End: 2027-06-30Target: 20Updated: 2026-01-21

Antisecretory Factor Glioblastoma Phase 2

RecruitingNCT05669820

Peter SiesjöGlioblastoma

Start: 2024-01-15End: 2027-12-01Target: 300Updated: 2026-01-09

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

RecruitingNCT07364786

Peter SiesjöGlioblastoma

Start: 2024-10-07End: 2026-11-01Target: 10Updated: 2026-01-23

Phase 3

Antisecretory Factor (AF) Effects on Intraocular-pressure

TerminatedNCT02731118

St. Erik Eye HospitalGlaucoma

Start: 2016-04-30End: 2020-12-31Target: 50Updated: 2021-05-14

Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury

CompletedNCT03339505

Peter SiesjöBrain Trauma

Start: 2017-09-17End: 2022-10-10Updated: 2022-10-12

Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer

Henrik LindmanAdverse Drug Event, Diarrhea, Early-stage Breast Cancer

Start: 2023-06-07End: 2025-03-31Target: 100Updated: 2023-11-30

Related Papers

Salovum® reduces mortality in isolated severe traumatic brain injury: a randomized phase II trial.

2026-09-07

Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial

Trials2025-03-13

Antisecretory factor in severe traumatic brain injury (AFISTBI): protocol for an exploratory randomized placebo-controlled trial.

2025-02-07

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma

BMC Neurology2023-02-182 citations

Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial.

2022-04-232 citations